Abstract

Remission is the goal of modern asthma treatment. Allergen immunotherapy (AIT) is an essential component in the armamentarium of personalized asthma therapy. Subcutaneous AIT (SCIT) or sublingual AIT (SLIT) offer the possibility to prevent asthma in patients with allergic rhinitis (reduction of the risk of developing asthma) and the possibility to achieve remission in patients with allergic asthma. Accordingly, AIT should always be considered in patients with asthma and a documented, clinically relevant allergy. However, precise phenotyping of the patient is an essential prerequisite for a success of AIT in asthma.

Author Details

Authors

• J. Christian Virchow¹
• Oliver Pfaar²
• Marek Lommatzsch¹

Departments

• ¹ Department of Pneumology, Rostock University Medical Centre, University of Rostock, Rostock, and
• ² Clinic for Ear, Nose and Throat Medicine, University Hospital Giessen and Marburg GmbH, Marburg site, Philipps University Marburg, Marburg

Address

Prof. Dr. Marek Lommatzsch, Leitender Oberarzt und Stellvertretender Klinikdirektor, Department of Pneumology, Center for Internal Medicine, Rostock University Medical Center, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
Email: [email protected]

Citation